Enterprise Value

429.6B

Cash

3.725B

Avg Qtr Burn

N/A

Short % of Float

0.77%

Insider Ownership

0.15%

Institutional Own.

84.00%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Jaypirca (pirtobrutinib) Details
Blood cancer, Cancer, Lymphoma, Mantle cell lymphoma

Approved

Quarterly sales

PDUFA

Approval decision

Mirikizumab Details
Ulcerative colitis

BLA

Resubmission

Donanemab Details
Alzheimer's disease

NDA

Submission

Mirikizumab Details
Crohns disease

Phase 3

Data readout

Abemaciclib Details
Castration-resistant prostate cancer

Phase 3

Data readout

Phase 3

Data readout

Phase 3

Update

Lebrikizumab Details
Skin disease/disorder, Atopic dermatitis

Phase 3

Update

Phase 2

Update

Peresolimab /LY3462817 Details
Rheumatoid arthritis, Autoimmune disease

Phase 2

Update

AK-OTOF Details
OTOF-mediated hearing loss

Phase 1

Update